Botanicals in Postmenopausal Osteoporosis

Osteoporosis is a systemic bone disease characterized by reduced bone mass and the deterioration of bone microarchitecture leading to bone fragility and an increased risk of fractures. Conventional anti-osteoporotic pharmaceutics are effective in the treatment and prophylaxis of osteoporosis, however they are associated with various side effects that push many women into seeking botanicals as an alternative therapy. Traditional folk medicine is a rich source of bioactive compounds waiting for discovery and investigation that might be used in those patients, and therefore botanicals have recently received increasing attention. The aim of this review of literature is to present the comprehensive information about plant-derived compounds that might be used to maintain bone health in perimenopausal and postmenopausal females.     

Zinc Pharmacotherapy for Elderly Osteoporotic Patients with Zinc Deficiency in a Clinical Setting

Although there have been reported associations between zinc and bone mineral density (BMD), no reports exist on the effect of zinc treatment in osteoporotic patients. Therefore, we investigated the efficacy and safety of zinc pharmacotherapy in Japanese elderly patients. The present investigation included 122 osteoporotic patients with zinc deficiency, aged ≥65 years, who completed 12 months of follow-up. In addition to standard therapy for osteoporosis in a clinical setting, the subjects received oral administration of 25 mg zinc (NOBELZIN^®, an only approved drug for zinc deficiency in Japan) twice a day. BMD and laboratory data including bone turnover markers were collected at 0 (baseline), 6, and 12 months of zinc treatment. Neither serious adverse effects nor incident fractures were seen during the observation period. Serum zinc levels were successfully elevated by zinc administration. BMD increased significantly from baseline at 6 and 12 months of zinc treatment. Percentage changes of serum zinc showed significantly positive associations with those of BMD. Bone formation markers rose markedly from the baseline values, whereas bone resorption markers displayed moderate or no characteristic changes. Additive zinc supplementation may contribute to BMD augmentation ensuing the prevention of fracture occurrence in elderly osteoporotic patients with zinc deficiency.     

A Three-Year Longitudinal Study Comparing Bone Mass,Density, and Geometry Measured by DXA,pQCT, and Bone Turnover Markers in Children with PKU Taking L-Amino Acid or Glycomacropeptide Protein Substitutes

In patients with phenylketonuria (PKU), treated by diet therapy only, evidence suggests that areal bone mineral density (BMDa) is within the normal clinical reference range but is below the population norm. Aims: To study longitudinal bone density, mass, and geometry over 36 months in children with PKU taking either amino acid (L-AA) or casein glycomacropeptide substitutes (CGMP-AA) as their main protein source. Methodology: A total of 48 subjects completed the study, 19 subjects in the L-AA group (median age 11.1, range 5–16 years) and 29 subjects in the CGMP-AA group (median age 8.3, range 5–16 years). The CGMP-AA was further divided into two groups, CGMP100 (median age 9.2, range 5–16 years) (n = 13), children taking CGMP-AA only and CGMP50 (median age 7.3, range 5–15 years) (n = 16), children taking a combination of CGMP-AA and L-AA. Dual X-ray absorptiometry (DXA) was measured at enrolment and 36 months, peripheral quantitative computer tomography (pQCT) at 36 months only, and serum blood and urine bone turnover markers (BTM) and blood bone biochemistry at enrolment, 6, 12, and 36 months. Results: No statistically significant differences were found between the three groups for DXA outcome parameters, i.e., BMDa (L2–L4 BMDa g/cm²), bone mineral apparent density (L2–L4 BMAD g/cm³) and total body less head BMDa (TBLH g/cm²). All blood biochemistry markers were within the reference ranges, and BTM showed active bone turnover with a trend for BTM to decrease with increasing age. Conclusions: Bone density was clinically normal, although the median z scores were below the population mean. BTM showed active bone turnover and blood biochemistry was within the reference ranges. There appeared to be no advantage to bone density, mass, or geometry from taking a macropeptide-based protein substitute as compared with L-AAs.     

Associations of Lifestyle Factors with Osteopenia and Osteoporosis in Polish Patients with Inflammatory Bowel Disease

Reduced physical activity (PA), smoking, and coffee and alcohol drinking constitute risk factors of osteoporosis in patients with inflammatory bowel disease (IBD). The aim of the study was to measure the bone mineral density (BMD) and frequency of osteopenia and osteoporosis in patients with IBD and their correlation with PA, smoking, coffee, and alcohol. The study group consisted of 208 patients with IBD-103 with Crohn’s disease (CD), 105 suffering from ulcerative colitis (UC). Densitometric measurements were performed using the DXA. All patients completed a questionnaire concerning PA, smoking, and coffee and alcohol consumption. The prevalence of osteopenia and osteoporosis (L2–L4) in the IBD group was 48.1%; in the CD group, it amounted to 48.6%, and in the UC group, the prevalence was equal to 33.3%. Patients with CD who were diagnosed with osteopenia and osteoporosis demonstrated reduced PA compared to patients with a normal BMD who exercised regularly (p = 0.0335). A similar observation was made in the group of women with IBD. Women with a normal BMD exercised significantly more often than women suffering from osteopenia and osteoporosis (p = 0.0146). However, no differences in BMD were observed with regard to coffee use, alcohol consumption, or smoking. Thus, since the incidence of osteoporosis in IBD patients is high, it may be dependent on PA.     

2011—2019年不同时期荆州市一二期梅毒时空特征对比分析

目的 分析荆州市不同时期一二期梅毒的时空分布变化情况,为合理配置卫生资源提供参考。方法 收集2011—2019年荆州市一二期梅毒疫情资料,根据发病率高低,将荆州市一二期梅毒疫情分为2011—2013年（高）、2014—2016年（中）、2017—2019年（低）3个时期,采取趋势面、空间自相关和时空扫描分析3个时期一二期梅毒在时空上的变化趋势。结果 2011—2019年,荆州市累计报告一二期梅毒4 715例,年均发病率为9.19/10万,发病率呈下降趋势（P<0.01）。趋势面分析得出荆州市一二期梅毒的高发区域逐步从西北部（2011—2013年）向中部转移（2017—2019年）。全局空间自相关分析显示,荆州市一二期梅毒发病率在2011—2013年、2014—2016年呈正相关,且有空间聚集性（Moran’s I=0.333 6、0.210 5,均P<0.01）。局部空间自相关分析显示,一二期梅毒高值聚集区2011—2013年主要集中在公安县、荆州区、沙市区、江陵县的部分乡镇（P<0.05）,2014—2016年主要集中在荆州区、沙市区、监利县的部分乡镇（P<0.05）,2017—2019年主要集中在监利县、沙市区的部分乡镇（P<0.05）。时空扫描结果显示,主聚集区在公安县、江陵县,共24个乡镇（街道）,聚集时间为2011年4月11日至2011年8月15日（RR=4.14,LLR=93.55）。结论 3个时期荆州市一二期梅毒均存在空间聚集性,高发区域逐步缩小,2017—2019年监利县、沙市区的部分乡镇为疫情高发地区,应加强对该地区的防控工作。     

基于DRGs的医疗服务绩效差异分析:以二级综合医院为例

目的对成都市二级民营综合医院与公立综合医院住院医疗服务绩效进行DRGs分析和比较,找出差异,提出建议。方法收集2019年成都市二级民营综合医院和二级公立综合医院住院病案首页数据,利用四川省DRGs应用平台进行分组计算,使用SPSS 20.0软件进行指标分析。结果成都市二级民营综合医院与二级公立综合医院2019年住院医疗服务绩效在医疗服务（总权重、覆盖DRGs组数和CMI值）、医疗效率（时间消耗指数、费用消耗指数）上并无显著差异,但在医疗质量与安全（中低风险及以下组病死率、标化病死率）上差异明显。结论二级民营综合医院与二级公立综合医院整体医疗服务差距逐渐缩小;二级民营综合医院内部发展不均衡,医疗质量与安全水平低于二级公立综合医院。建议持续提升民营综合医院服务能力,加强民营综合医院医疗质量与安全管理,同时政府须对民营医院强化监管。     

慢性肾功能衰竭患者血清C—PTH变化与并发症的关系探讨

探讨慢性肾功能衰竭(CRF)患者血清羧基端甲状旁腺素(C-PTH)的变化及与钙磷代谢、高血压和贫血的关系。方法44例CRF患者用放免法测定血清C-PTH,血清尿素氮(BUN)、血清肌酐(Scr)、血清钙(Ca     

脉冲电磁场治疗绝经后骨质疏松症46例临床观察

目的 :对脉冲电磁场 (PEMFs)治疗绝经后骨质疏松症疗效进行观察和探讨。方法 :对本院骨科门诊相关绝经后的妇女进行骨质疏松症问卷调查及跟骨骨密度 (BMD)及相关生化项目检测而确诊为绝经后骨质疏松症患者进行PEMFS治疗 ,治疗中及治疗后观察其自觉症状改善情况及骨密度的变化 ,并与治疗前对比分析。结果 :① 10 0 %患者疼痛明显减轻 ,② 76 .0 1%患者治疗后BMD增加 >5 .6 %以上。结论 :PEMFS治疗绝经骨质疏松症可有效控制疼痛 ,提高患者存在的质量 ,对患者骨密度也有一定程度的提高     

原发性高血压患者骨量减少机制初探

为探讨原发性高血压 (EH)与骨量减少的关系 ,采用双能X线骨密度仪测定了 1 2 1例肝、肾功能正常的EH患者的腰椎 (L2 ～L4 )、股骨上端的骨密度 (BMD) ;采用放免法测定血清骨钙素 (BGP)、甲状旁腺素中间片段 (PTH m) ;采用酶免法测定尿脱氧吡啶啉 (DPD)。结果 :EH病人骨密度均低于正常对照组 ,除女性≤ 4 0岁组外P均 <0 .0 1 ;血清BGP、PTH m、DPD均高于正常对照组 (P <0 .0 1 ) ;且BGP、PTH m、DPD与骨密度呈负相关 ,r分别为 -0 .30 7、-0 .2 68、-0 .2 51 (P <0 .0 1 ) ;而血清钙、磷、碱性磷酸酶与正常对照组无显著差异 (P >0 .0 5) ;男女EH病人骨量减少检出率分别为 4 4.83%及 36.50 % ,骨质疏松检出率分别为 6.90 %及 2 6.98% ,且以股骨上端华氏三角区骨量减少为著。结论 :EH病人存在钙、磷代谢紊乱 ,可导致骨量减少 ,以骨吸收大于骨形成、高骨转换为特点。提示在治疗高血压的同时应补充活性维生素D及钙剂 ,防治骨质疏松的发生。